Right Ventricular Reverse Remodeling After Transcatheter Tricuspid Valve Replacement in Patients With Heart Failure

Ludwig T. Weckbach; Lukas Stolz; Andrew G. Chatfield; Neil P. Fam; Ralph Stephan von Bardeleben; Charles J. Davidson; Rebecca T. Hahn; Jörg Hausleiter

doi:10.1016/j.jacc.2022.12.005

Right Ventricular Reverse Remodeling After Transcatheter Tricuspid Valve Replacement in Patients With Heart Failure

Ludwig T. Weckbach^*, Lukas Stolz, Andrew G. Chatfield, Neil P. Fam, Ralph Stephan von Bardeleben, Charles J. Davidson, Rebecca T. Hahn, Jörg Hausleiter

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English (US)
Pages (from-to)	708-710
Number of pages	3
Journal	Journal of the American College of Cardiology
Volume	81
Issue number	7
DOIs	https://doi.org/10.1016/j.jacc.2022.12.005
State	Published - Feb 21 2023

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2022.12.005

Cite this

@article{e7f90a32491242538a586a8293624ed5,

title = "Right Ventricular Reverse Remodeling After Transcatheter Tricuspid Valve Replacement in Patients With Heart Failure",

author = "Weckbach, {Ludwig T.} and Lukas Stolz and Chatfield, {Andrew G.} and Fam, {Neil P.} and {Stephan von Bardeleben}, Ralph and Davidson, {Charles J.} and Hahn, {Rebecca T.} and J{\"o}rg Hausleiter",

note = "Funding Information: Dr Weckbach has received speaker honoraria from AstraZeneca and Bayer. Dr Chatfield is funded by the New Zealand Heart Foundation and John Ormiston Scholarship. Dr Fam is a consultant to Edwards, Abbott, and Cardiovalve. Dr von Bardeleben has received research grants and honoraria from Abbott Structural Heart, Edwards Lifesciences, and NeoChord; all trial activity is without personal reimbursement. Dr Davidson has received research grant support from Edwards Lifesciences; and is an uncompensated consultant to Edwards. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Dr Hausleiter has received speaker honoraria from and serves as consultant for Abbott Vascular and Edwards Lifesciences. Dr Stolz has reported that he has no relationships relevant to the contents of this paper to disclose. The authors thank Michael N{\"a}bauer, MD, Philipp Doldi, MD, John G. Webb, MD, Geraldine Ong, MD, Mark Peterson, MD, Djeven P. Deva, MD, Tobias Ruf, MD, Mark A. Lebehn, MD, Susheel K. Kodali, MD, Philipp Blanke, MD, Stefan Maurus, MD, for their contribution to this study. ",

year = "2023",

month = feb,

day = "21",

doi = "10.1016/j.jacc.2022.12.005",

language = "English (US)",

volume = "81",

pages = "708--710",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Right Ventricular Reverse Remodeling After Transcatheter Tricuspid Valve Replacement in Patients With Heart Failure

AU - Weckbach, Ludwig T.

AU - Stolz, Lukas

AU - Chatfield, Andrew G.

AU - Fam, Neil P.

AU - Stephan von Bardeleben, Ralph

AU - Davidson, Charles J.

AU - Hahn, Rebecca T.

AU - Hausleiter, Jörg

N1 - Funding Information: Dr Weckbach has received speaker honoraria from AstraZeneca and Bayer. Dr Chatfield is funded by the New Zealand Heart Foundation and John Ormiston Scholarship. Dr Fam is a consultant to Edwards, Abbott, and Cardiovalve. Dr von Bardeleben has received research grants and honoraria from Abbott Structural Heart, Edwards Lifesciences, and NeoChord; all trial activity is without personal reimbursement. Dr Davidson has received research grant support from Edwards Lifesciences; and is an uncompensated consultant to Edwards. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Dr Hausleiter has received speaker honoraria from and serves as consultant for Abbott Vascular and Edwards Lifesciences. Dr Stolz has reported that he has no relationships relevant to the contents of this paper to disclose. The authors thank Michael Näbauer, MD, Philipp Doldi, MD, John G. Webb, MD, Geraldine Ong, MD, Mark Peterson, MD, Djeven P. Deva, MD, Tobias Ruf, MD, Mark A. Lebehn, MD, Susheel K. Kodali, MD, Philipp Blanke, MD, Stefan Maurus, MD, for their contribution to this study.

PY - 2023/2/21

Y1 - 2023/2/21

UR - http://www.scopus.com/inward/record.url?scp=85147414318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147414318&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2022.12.005

DO - 10.1016/j.jacc.2022.12.005

M3 - Letter

C2 - 36792287

AN - SCOPUS:85147414318

SN - 0735-1097

VL - 81

SP - 708

EP - 710

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 7

ER -

Right Ventricular Reverse Remodeling After Transcatheter Tricuspid Valve Replacement in Patients With Heart Failure

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this